|
Parameter
|
≤ Normal
|
Overweight
|
Obese
|
p-value
|
|---|
|
Number
|
63
|
73
|
86
| |
|
Age (years)
|
68.57 ± 6.06
|
68.07 ± 6.85
|
67.07 ± 5.76
|
0.321
|
|
IOM (mm2/cm2)
|
10.84 ± 2.18
|
11.13 ± 2.02
|
11.59 ± 2.37
|
0.115
|
|
BMI (kg/m2)
|
21.11 ± 1.45
|
24.06 ± 0.51
|
27.25 ± 1.79
|
< 0.001
|
|
Pre-op PSA (ng/mL)
|
13.97 ± 17.97
|
11.01 ± 10.93
|
10.40 ± 10.57
|
0.237
|
|
Prostate volume (cc)
|
32.54 ± 12.95
|
33.01 ± 14.39
|
37.54 ± 14.42
|
0.062
|
|
Type of operation
| | | |
0.291
|
|
RRP
|
48 (76.2)
|
58 (79.5)
|
57 (66.3)
| |
|
LRP
|
0 (0.0)
|
0 (0.0)
|
1 (1.2)
| |
|
RARP
|
15 (23.8)
|
15 (20.5)
|
28 (32.6)
| |
|
Gleason score
| | | |
0.165
|
|
≤ 6
|
14 (22.2)
|
20 (27.4)
|
25 (29.1)
| |
|
7
|
43 (68.3)
|
49 (67.1)
|
53 (61.6)
| |
|
8
|
5 (7.9)
|
1 (1.4)
|
2 (2.3)
| |
|
9
|
1 (1.6)
|
3 (4.1)
|
6 (7.0)
| |
|
T-stage
| | | |
0.220
|
|
T2a
|
7 (11.1)
|
14 (19.2)
|
7 (8.1)
| |
|
T2b
|
7 (11.1)
|
13 (17.8)
|
18 (20.9)
| |
|
T2c
|
37 (58.7)
|
37 (50.7)
|
45 (52.3)
| |
|
T3a
|
5 (7.9)
|
5 (6.8)
|
11 (12.8)
| |
|
T3b
|
7 (11.1)
|
4 (5.5)
|
5 (5.8)
| |
|
N-stage
| | | |
0.524
|
|
0
|
62 (98.4)
|
72 (98.6)
|
86 (100)
| |
|
1
|
1 (1.6)
|
1 (1.4)
|
0 (0.0)
| |
|
cM stage
| | | |
0.282
|
|
0
|
62 (98.4)
|
73 (100)
|
86 (100.0)
| |
|
1
|
1 (1.6)
|
0 (0.0)
|
0 (0.0)
| |
|
BCR
| | | |
0.521
|
|
0
|
46 (73.0)
|
59 (80.8)
|
68 (79.1)
| |
|
1
|
17 (27.0)
|
14 (19.2)
|
18 (20.9)
| |
- IOM, Internal obturator muscle mass index; BMI, body mass index; pre-op PSA, pre-operative prostate-specific antigen; RRP, radical retropubic prostatectomy; LRP, laparoscopic radical prostatectomy; RARP, robot-assisted radical prostatectomy; BCR, biochemical recurrence
